FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385690625> ?p ?o ?g. }

• W4385690625 abstract "BMI affects breast cancer risk and prognosis. In contrast to cytotoxic chemotherapy, CDK4/6 inhibitors are given at a fixed dose, irrespective of BMI or weight. This preplanned analysis of the global randomized PALLAS trial investigates the impact of BMI on the side-effect profile, treatment adherence, and efficacy of palbociclib.Patients were categorized at baseline according to WHO BMI categories. Neutropenia rates were assessed with univariable and multivariable logistic regression. Time to early discontinuation of palbociclib was analyzed with Fine and Gray competing risk models. Unstratified Cox models were used to investigate the association between BMI category and time to invasive disease-free survival (iDFS). 95% CIs were derived.Of 5,698 patients included in this analysis, 68 (1.2%) were underweight, 2,082 (36.5%) normal weight, 1,818 (31.9%) overweight, and 1,730 (30.4%) obese at baseline. In the palbociclib arm, higher BMI was associated with a significant decrease in neutropenia (unadjusted odds ratio for 1-unit change, 0.93; 95% CI, 0.91 to 0.94; adjusted for age, race ethnicity, region, chemotherapy use, and Eastern Cooperative Oncology Group at baseline, 0.93; 95% CI, 0.92 to 0.95). This translated into a significant decrease in treatment discontinuation rate with higher BMI (adjusted hazard ratio [HR] for 10-unit change, 0.75; 95% CI, 0.67 to 0.83). There was no significant improvement in iDFS with the addition of palbociclib to ET in any weight category (normal weight HR, 0.84; 95% CI, 0.63 to 1.12; overweight HR, 1.10; 95% CI, 0.82 to 1.49; and obese HR, 0.95; 95% CI, 0.69 to 1.30) in this analysis early in follow-up (31 months).This preplanned analysis of the PALLAS trial demonstrates a significant impact of BMI on side effects, dose reductions, early treatment discontinuation, and relative dose intensity. Additional long-term follow-up will further evaluate whether BMI ultimately affects outcome." @default.
• W4385690625 created "2023-08-10" @default.
• W4385690625 creator A5001617286 @default.
• W4385690625 creator A5004874011 @default.
• W4385690625 creator A5005537242 @default.
• W4385690625 creator A5006619488 @default.
• W4385690625 creator A5007199258 @default.
• W4385690625 creator A5007286394 @default.
• W4385690625 creator A5007290313 @default.
• W4385690625 creator A5007834910 @default.
• W4385690625 creator A5008549101 @default.
• W4385690625 creator A5008665323 @default.
• W4385690625 creator A5013406094 @default.
• W4385690625 creator A5015052494 @default.
• W4385690625 creator A5019041034 @default.
• W4385690625 creator A5021313237 @default.
• W4385690625 creator A5025554206 @default.
• W4385690625 creator A5025718393 @default.
• W4385690625 creator A5026024346 @default.
• W4385690625 creator A5031366322 @default.
• W4385690625 creator A5033700679 @default.
• W4385690625 creator A5035683674 @default.
• W4385690625 creator A5036695602 @default.
• W4385690625 creator A5038355731 @default.
• W4385690625 creator A5038918684 @default.
• W4385690625 creator A5039097727 @default.
• W4385690625 creator A5042829808 @default.
• W4385690625 creator A5045869189 @default.
• W4385690625 creator A5050495040 @default.
• W4385690625 creator A5055013606 @default.
• W4385690625 creator A5055292882 @default.
• W4385690625 creator A5055301443 @default.
• W4385690625 creator A5060036762 @default.
• W4385690625 creator A5060114464 @default.
• W4385690625 creator A5060320368 @default.
• W4385690625 creator A5061761089 @default.
• W4385690625 creator A5063891717 @default.
• W4385690625 creator A5067418473 @default.
• W4385690625 creator A5067468792 @default.
• W4385690625 creator A5067642403 @default.
• W4385690625 creator A5068666503 @default.
• W4385690625 creator A5069669113 @default.
• W4385690625 creator A5070245248 @default.
• W4385690625 creator A5070704228 @default.
• W4385690625 creator A5071176191 @default.
• W4385690625 creator A5073728088 @default.
• W4385690625 creator A5075134210 @default.
• W4385690625 creator A5082509731 @default.
• W4385690625 creator A5082786838 @default.
• W4385690625 creator A5082951649 @default.
• W4385690625 creator A5084303748 @default.
• W4385690625 creator A5084357214 @default.
• W4385690625 creator A5086013063 @default.
• W4385690625 creator A5086400759 @default.
• W4385690625 creator A5086817452 @default.
• W4385690625 creator A5087559224 @default.
• W4385690625 creator A5089113899 @default.
• W4385690625 creator A5089513581 @default.
• W4385690625 creator A5090009905 @default.
• W4385690625 creator A5090188675 @default.
• W4385690625 date "2023-08-09" @default.
• W4385690625 modified "2023-10-13" @default.
• W4385690625 title "Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial" @default.
• W4385690625 cites W1997546288 @default.
• W4385690625 cites W2024021877 @default.
• W4385690625 cites W2089501709 @default.
• W4385690625 cites W2103213014 @default.
• W4385690625 cites W2113493868 @default.
• W4385690625 cites W2115138807 @default.
• W4385690625 cites W2116902655 @default.
• W4385690625 cites W2122689446 @default.
• W4385690625 cites W2124496014 @default.
• W4385690625 cites W2136158663 @default.
• W4385690625 cites W2149466392 @default.
• W4385690625 cites W2170585132 @default.
• W4385690625 cites W2552099557 @default.
• W4385690625 cites W2606033893 @default.
• W4385690625 cites W2740616896 @default.
• W4385690625 cites W2763875663 @default.
• W4385690625 cites W2767600184 @default.
• W4385690625 cites W2802776309 @default.
• W4385690625 cites W2898085761 @default.
• W4385690625 cites W2902212958 @default.
• W4385690625 cites W2904686713 @default.
• W4385690625 cites W2950856878 @default.
• W4385690625 cites W3048214562 @default.
• W4385690625 cites W3120241209 @default.
• W4385690625 cites W3127345676 @default.
• W4385690625 cites W3162334759 @default.
• W4385690625 cites W4200066800 @default.
• W4385690625 cites W4207025862 @default.
• W4385690625 cites W4211123279 @default.
• W4385690625 cites W4226029896 @default.
• W4385690625 doi "https://doi.org/10.1200/jco.23.00126" @default.
• W4385690625 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37556775" @default.
• W4385690625 hasPublicationYear "2023" @default.
• W4385690625 type Work @default.
• W4385690625 citedByCount "1" @default.
• W4385690625 crossrefType "journal-article" @default.
• W4385690625 hasAuthorship W4385690625A5001617286 @default.

• next